Jazz Pharmaceuticals (JAZZ) Cash & Equivalents (2010 - 2026)

Jazz Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 0.95% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (down 0.95% YoY), while the FY2025 annual figure was $1.4 billion, down 42.31% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.8 billion, up from $1.4 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $2.4 billion in Q4 2024, with the low at $490.8 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $1.3 billion (2023), against an average of $1.4 billion.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 76.6% in 2022, then jumped 137.94% in 2023.
• Jazz Pharmaceuticals' Cash & Equivalents stood at $881.5 million in 2022, then jumped by 70.88% to $1.5 billion in 2023, then soared by 60.18% to $2.4 billion in 2024, then plunged by 42.31% to $1.4 billion in 2025, then jumped by 32.5% to $1.8 billion in 2026.
• Business Quant data shows JAZZ's Cash & Equivalents at $1.8 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.3 billion in Q3 2025.